Been following the IgA nephropathy space for a bit, and Novartis just dropped some solid phase 3 data that's worth paying attention to. The ALIGN trial results for Vanrafia show meaningful improvements in kidney function decline among IgA nephropathy patients, which is actually pretty significant given how progressive this disease is.

For context, IgA nephropathy is one of those autoimmune kidney diseases that doesn't get as much mainstream attention as it probably should. We're talking roughly 25 per million people getting newly diagnosed each year globally. The disease basically triggers inflammation in your kidney filters, leads to excess protein in urine, and gradually tanks your glomerular filtration rate. It's a slow but relentless decline if left unchecked.

What caught my eye about the ALIGN results is the consistency. At week 132, Vanrafia showed a 2.59 mL/min/1.73 m² improvement in eGFR compared to placebo, and this held even for patients already on SGLT2 inhibitors. More interesting, the benefits persisted at week 136, four weeks after treatment ended, with a 2.39 mL/min/1.73 m² improvement. That kind of durability matters when you're dealing with a chronic disease like IgA nephropathy.

Vanrafia actually got accelerated FDA approval last year for proteinuria reduction in primary IgA nephropathy, and China approved it too. Now Novartis is going for traditional approval this year based on these phase 3 results. The company's framing this as a potential foundational therapy, which suggests they see it as something that could become standard of care for IgA nephropathy management.

On the financial side, Novartis reported 2025 earnings of $17.41 billion in core net income ($8.98 per share) versus $15.76 billion in 2024, with net sales hitting $54.53 billion, up 8% year-over-year. Stock closed around $161.18 yesterday. From a biotech investment angle, positive phase 3 data on kidney disease treatments tends to get decent market reception, especially if the drug can become a foundational therapy for something as significant as IgA nephropathy management. Worth keeping on the radar.